Humanis Expands Into China

Humanis Expands into China Humanis becomes the first Turkish company to export pharmaceuticals to China while maintaining EU quality standards Exporting to 25 countries across 3 continents, Humanis is strengthening its global reach. One of Turkey's fastest-growing pharmaceutical companies, Humanis took its first step toward entering China, a challenging market, thanks to its manufacturing expertise aligned with European Union quality standards. CEO Yunus Sancak made a statement on the matter: "The Chinese market holds significant potential for Turkish manufacturers. As a company that has proven its strength on a global scale through both our production capacity and R&D investments, we are ready to claim our place in this market. It is highly valuable for our country and sector that a strong nation like China, despite having EU standard production capabilities itself, chose Humanis. In the coming periods, we aim to accelerate our steps in China by strengthening our investments," he said. Humanis made a strong entry into the pharmaceutical sector in 2010 with an investment of approximately USD 200 million and is working hard to make its human-centered health philosophy accessible worldwide. Through its investments and an important production facility located in Çerkezköy, Humanis has become one of Turkey's fastest-growing pharmaceutical companies. With its GMP (Good Manufacturing Practices) certifications, Humanis provides manufacturing services to global companies and has quickly become one of the effective players in both domestic and foreign markets.

Yunus Sancak: "We Have Taken Important Steps in Exports So Far"

Speaking about Humanis's production principles, CEO Yunus Sancak said: "We continue to expand our investments and acquisitions in line with Humanis's human-centered health philosophy strategy. Today, thanks to our experienced team, production capacity and technological infrastructure, we have reached a position where we can produce pharmaceuticals in many forms. As a member of domestic production gaining increasing value, we have been taking important steps in exports for a long time." Yunus Sancak, who stated "We export to 25 countries across 3 continents, including countries such as Germany, the United Kingdom, Italy and Spain. We have started our efforts to sell our products directly to the European market through our office established in Germany," emphasized that Turkey has a market share capable of exporting pharmaceuticals to hundreds of countries thanks to its advanced pharmaceutical industry.

Yunus Sancak: "We Became the First Company to Export Pharmaceuticals from Turkey to China"

Speaking in the manner of "While China must provide affordable and accessible medicines for its population approaching 1.5 billion, it must also encourage the growth of the pharmaceutical industry. For this reason, generic pharmaceuticals form the foundation of China's pharmaceutical industry," Yunus Sancak continued his assessment of the Chinese market as follows: "The Chinese market holds significant potential for Turkish manufacturers. As a company that has proven its strength on a global scale through both our production capacity and R&D investments, we are ready to claim our place in this market. We took our first step recently with one of our products and thus became the first company to export pharmaceuticals from Turkey to China. In the coming periods, we aim to accelerate our steps in China by strengthening our investments. As one of Turkey's largest generic pharmaceutical manufacturers, we view the Chinese market as a major opportunity."

Yunus Sancak: "We Target USD 5 Million in Sales in the Initial Phase"

Yunus Sancak explained that they took their first step to China with a pharmaceutical used in the fields of cardiology and chest diseases, stating: "For the development, licensing and preparation of the necessary infrastructure for commercial production of this product, we invested approximately USD 2.3 million. With this product in the Chinese market, we aim to achieve USD 5 million in sales in the initial phase. We will continuously invest this profit in growth and development, and will increase the number of licensed products we export to China in the shortest possible time." Humanis, which holds GMP certifications from Germany, Belgium, Canada and Russia, has products under licensing development for the markets of the United Arab Emirates, Saudi Arabia, Kuwait, Jordan, the Philippines, Kyrgyzstan, Ukraine and Russia, with sales to begin soon. In the coming period, the company plans to increase its current exports to Europe and has begun preparations to enter the US and South American markets.